New-Onset Chronic Musculoskeletal Pain Following COVID-19 Infection Fulfils the Fibromyalgia Clinical Syndrome Criteria: A Preliminary Study.

New-Onset Chronic Musculoskeletal Pain Following COVID-19 Infection Fulfils the Fibromyalgia Clinical Syndrome Criteria: A Preliminary Study.

Publication date: Aug 23, 2024

New-onset chronic musculoskeletal (MSK) pain (>3 months duration) is a common symptom of post-COVID-19 syndrome (PCS). This study aimed to characterise new-onset chronic MSK pain in patients with PCS and its overlap with Fibromyalgia Syndrome (FMS). We enrolled patients with new-onset chronic MSK pain post-COVID-19 and assessed the nature of the pain and associated symptoms using the C19-YRS (Yorkshire Rehabilitation Scale). The FMS assessment was conducted as part of a standard clinical examination using the American College of Rheumatology (ACR) 2010 criteria: (1) Widespread Pain Index (WPI) ≥ 7 and symptoms severity (SS) score ≥ 5, or WPI between 3 and 6 and SS score ≥ 9, (2) symptoms consistent for at least 3 months, and (3) no alternative diagnosis. Of the eighteen patients (average age 49. 6 (SD 11. 8) years; BMI 31. 7 (SD 8. 6)), twelve were female. The average symptom duration was 27. 9 (SD 6. 97) months post-infection. Thirteen patients (72. 2%) met the FMS criteria, with an average WPI score of 8. 8 and an average SS score of 8. 2, indicating a high level of pain and significant quality of life impacts. These findings support the hypothesis that FMS may develop as a long-term sequela of a viral infection, underscoring the need for further research into post-viral long-term conditions.

Open Access PDF

Concepts Keywords
American chronic pain
Biomedicines chronic widespread pain
Fibromyalgia FM syndrome
Months long COVID
Viral post-acute sequela
post-COVID-19 condition

Semantics

Type Source Name
disease MESH Musculoskeletal Pain
disease MESH COVID-19
disease MESH Infection
disease MESH Fibromyalgia
disease MESH Syndrome
disease IDO symptom
drug DRUGBANK Methionine
disease IDO quality
disease MESH viral infection
drug DRUGBANK LS11
disease MESH long COVID
disease MESH chronic pain
disease IDO acute infection
drug DRUGBANK Coenzyme M
disease MESH chronic condition
disease MESH osteoarthritis
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH hepatitis
disease MESH infectious diseases
disease IDO site
disease MESH marital status
disease MESH breathlessness
disease MESH post traumatic stress disorder
disease MESH anxiety
disease MESH depression
disease IDO role
disease MESH arthralgia

Original Article

(Visited 1 times, 1 visits today)